CLL Support Association
8,875 members14,188 posts

Dr Sharman's inaugural guest blog on Venclexta / Venetoclax / ABT-199, by Tom Boyd; Essential reading if you are considering this treatment

Dr Sharman's inaugural guest blog on Venclexta / Venetoclax / ABT-199, by Tom Boyd; Essential reading if you are considering this treatment

Considering treatment with Venclexta (or its myriad names) or Ibrurinib (and its myriad names) or ACP196/acalabrutinib (and I'm sure it will soon gain another name)?  Then make certain that you first read this guest blog:

cll-nhl.com/2016/04/venclex...

Incidentally, I'd suggest that the word 'except' was not intended in the first sentence of the section: 'Should I run off to the nearest major cancer center to be treated with this new agent?

If you do not have the 17-p deletion mutation, then at this time you could only receive this drug, except as part of a clinical trial.'

Neil

4 Replies
oldestnewest

Very interesting 

Thanks

Reply

It is early in the  testing of Venetoclax.  However, various researchers are talking about a cure by combining with a ACP-196 or Ibrutinib.  This means that you go off all medicine.  At the same time inexperienced doctors will kill patients as highlighted in the article due to tumor lysis.

1 like
Reply

Another good reason to see a CLL specialist when you need treatment...

Reply

Like my friend... Randy Shirley

patientpower.info/blog/pati...

Reply

You may also like...